Biogen: Update on Lecanemab Review by EC
Eisai provides update on European Commission's regulatory review of Lecanemab for early Alzheimer's.
Read full article »
Biogen is a Massachusetts-based biotechnology company that researches and develops novel therapies for the treatment of neurological diseases across the globe.
Read more